Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438775 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
A Phase 3 study, sponsored by Nymox Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
NCT01438775: Completed Phase 3 study, sponsored by Nymox Corporation.
NCT01438775 is a Phase 3 study that has completed, run by Nymox Corporation. The registered enrollment target is 192 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01438775, a Phase 3 study, has completed, sponsored by Nymox Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207 in an earlier U.S. clinical trial of NX-1207.
Interventions
- DRUG NX-1207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01438775
The ClinicalTrials.gov registry entry for NCT01438775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nymox Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NX-1207 is the first listed.
NCT01438775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01438775 about?
NCT01438775 is a clinical study titled "Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)". This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207 in an earlier U.S. clinical trial of NX-1207.
What is the current status of trial NCT01438775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2011-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01438775?
The interventions under investigation include: NX-1207 (DRUG).
Who is sponsoring clinical trial NCT01438775?
This trial is sponsored by Nymox Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.